Table 2. Logistic regression univariate and multivariate analysis of factors associated with treatment success in patients starting drug resistant-TB treatment (DR-TB) from 2008 to 2012.

Factor	Univariate analysis		Multivariate analysis
	Odds ratio (95% CI)	p-value	Adjusted odds ratio (95% CI)	p-value
HIV status
Uninfected	1.0 (reference)		1.0 (reference)
Infected	1.1 (0.80–1.5)	0.59	0.78 (0.54–1.1)	0.21
Gender
Male	1.0 (reference)		1.0 (reference)
Female	1.4 (1.0–1.8)	0.035	1.6 (1.1–2.2)	0.005
Age category (years)
<=15	3.0 (1.1–8.8)	0.039	2.1 (0.71–6.4)	0.17
16–24	0.62 (0.40–0.96)	0.032	0.57 (0.35–0.93)	0.024
25–34	1.0 (reference)		1.0 (reference)
35–44	1.3 (0.94–1.9)	0.10	1.5 (1.1–2.2)	0.024
>44	1.2 (0.74–1.8)	0.54	1.4 (0.86–2.2)	0.17
Disease site
PTB	1.0 (reference)		1.0 (reference)
EPTB	2.7 (1.5–5.0)	0.001	2.6 (1.4–5.1)	0.004
Both	1.9 (0.72–4.9)	0.19	2.0 (0.73–5.3)	0.18
Baseline smear status (if PTB)
Negative	1.0 (reference)		1.0 (reference)
Positive	0.77 (0.57–1.1)	0.10	0.86 (0.63–1.2)	0.36
Unknown	1.4 (0.65–3.1)	0.39	1.3 (0.61–3.0)	0.46
EPTB- no smear	2.4 (1.3–4.4)	0.007	NA	NA
DR-TB classification
Rifampicin-mono TBa	1.0 (reference)		1.0 (reference)
MDR-TBb	0.95 (0.67–1.3)	0.76	0.99 (0.68–1.4)	0.95
MDR-TB with second-line drug resistance	0.55 (0.33–0.90)	0.018	0.54 (0.32–0.91)	0.021
Previous TB treatment
No previous TB treatment	1.0 (reference)	NA	1.0 (reference)	NA
Previous first-line TB treatment	0.68 (0.50–0.92)	0.014	0.66 (0.47–0.91)	0.012

DR-TB: drug resistant TB; EPTB: extra-pulmonary TB; MDR-TB: multi-drug resistant TB; NA: not applicable; PTB: pulmonary TB.

^aIncludes unconfirmed GeneXpert rifampicin-resistant TB.

^bMDR-TB with no confirmed second-line resistance.